Recombinant AAV-Mediated BEST1 Transfer to the Retinal Pigment Epithelium: Analysis of Serotype-Dependent Retinal Effects

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Guziewicz, Karina E ^a   Zangerl, Barbara ^a,b   Komáromy, András M ^a,c   Iwabe, Simone ^a   Chiodo, Vincent A ^d   Boye, Sanford L ^d   Hauswirth, William W ^d   Beltran, William A ^a   Aguirre, Gustavo D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; PROTEIN BEST1; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEST1 GENE; BESTROPHINOPATHY; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; NONHUMAN; PIGMENT CELL; PIGMENT EPITHELIUM; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; RETINA DISEASE; SEROTYPE; TRANSGENE; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; CHLORIDE CHANNELS; DEPENDOVIRUS; DNA, RECOMBINANT; DOGS; EYE PROTEINS; GENETIC VECTORS; HUMANS; RETINAL PIGMENT EPITHELIUM; SAFETY; SEROTYPING; SPECIES SPECIFICITY; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84885449226     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075666     Document Type: Article

References (36)

1. Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, et al. (1998) Identification of the gene responsible for Best macular dystrophy. Nat Genet 19: 241-247.
2. Pianta MJ, Aleman TS, Cideciyan AV, Sunness JS, Li Y, et al. (2003) In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res 76: 203-211.
3. Kinnick TR, Mullins RF, Dev S, Leys M, Mackey DA, et al. (2011) Autosomal recessive vitelliform macular dystrophy in a large cohort of vitelliform macular dystrophy patients. Retina 31: 581-595.
4. Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, et al. (2000) Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A 97: 12758-12763.
5. Sun H, Tsunenari T, Yau KW, Nathans J, (2002) The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci U S A 99: 4008-4013.
6. Rosenthal R, Bakall B, Kinnick T, Peachey N, Wimmers S, et al. (2005) Expression of bestrophin-1, the product of the VMD2 gene, modulates voltage-dependent Ca2+ channels in retinal pigment epithelial cells. FASEB J 20: 178-180.
7. Milenkovic VM, Krejcova S, Reichhart N, Wagner A, Strauss O, (2011) Interaction of bestrophin-1 and Ca2+ channel β-subunits: identification of new binding domains on the bestrophin-1 C-terminus. PLoS One 6: e19364.
8. Hartzell HC, Qu Z, Yu K, Xiao Q, Chien LT, (2008) Molecular physiology of bestrophins: multifunctional membrane proteins linked to best disease and other retinopathies. Physiol Rev 88: 639-672.
9. Boon CJ, Klevering BJ, Leroy BP, Hoyng CB, Keunen JE, et al. (2009) The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Prog Retin Eye Res 28: 187-205.
10. Milenkovic VM, Röhrl E, Weber BH, Strauss O, (2011) Disease-associated missense mutations in bestrophin-1 affect cellular trafficking and anion conductance. J Cell Sci 124: 2988-2996.
11. Guziewicz KE, Zangerl B, Lindauer SJ, Mullins RF, Sandmeyer LS, et al. (2007) Bestrophin gene mutations cause canine multifocal retinopathy: a novel animal model for best disease. Invest Ophthalmol Vis Sci 48: 1959-1967.
12. Zangerl B, Wickström K, Slavik J, Lindauer SJ, Ahonen S, et al. (2010) Assessment of canine BEST1 variations identifies new mutations and establishes an independent bestrophinopathy model (cmr3). Mol Vis 16: 2791-2804.
13. Guziewicz KE, Slavik J, Lindauer SJ, Aguirre GD, Zangerl B, (2011) Molecular consequences of BEST1 gene mutations in canine multifocal retinopathy predict functional implications for human bestrophinopathies. Invest Ophthalmol Vis Sci 52: 4497-4505.
14. Guziewicz KE, Aguirre GD, Zangerl B, (2012) Modeling the structural consequences of BEST1 missense mutations. Adv Exp Med Biol 723: 611-618.
15. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
16. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
17. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, et al. (2008) Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19: 979-990.
18. Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, et al. (2012) Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130: 9-24.
19. Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, et al. (2005) Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 12: 1072-1082.
20. Auricchio A, Kobinger G, Anand V, Hildinger M, O'Connor E, et al. (2001) Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 10: 3075-3081.
21. Bitner H, Schatz P, Mizrahi-Meissonnier L, Sharon D, Rosenberg T, (2012) Frequency, genotype, and clinical spectrum of best vitelliform macular dystrophy: data from a national center in Denmark. Am J Ophthalmol 154: 403-412.
22. Best F, (1905) Ueber eine hereditaere Maculaaffektion. Z Augenheilk 13: 199-212.
23. Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, et al. (2001) Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28: 92-95.
24. Beltran WA, Boye SL, Boye SE, Chiodo VA, Lewin AS, et al. (2010) rAAV2/5 gene-targeting to rods: dose-dependent efficiency and complications associated with different promoters. Gene Ther 17: 1162-1174.
25. Beltran WA, Cideciyan AV, Lewin AS, Iwabe S, Khanna H, et al. (2012) Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci U S A 109: 2132-2137.
26. Kiang AS, Palfi A, Ader M, Kenna PF, Millington-Ward S, et al. (2005) Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol Ther 12: 555-561.
27. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS, (2007) Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res 47: 1202-1208.
28. Zhang Q, Acland GM, Wu WX, Johnson JL, Pearce-Kelling S, et al. (2002) Different RPGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration. Hum Mol Genet 11: 993-1003.
29. Aguirre GD and Acland GM (2006) Models, Mutants and Man: Searching for Unique Phenotypes and Genes in the Dog Model of Inherited Retinal Degeneration. Cold Spring Harbor: Cold Spring Harbor Laboratory Press. 291-325.
30. Miyadera K, Acland GM, Aguirre GD, (2012) Genetic and phenotypic variations of inherited retinal diseases in dogs: the power of within- and across-breed studies. Mamm Genome 23: 40-61.
31. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N, (1996) A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70: 4646-4654.
32. Esumi N, Oshima Y, Li Y, Campochiaro PA, Zack DJ, (2004) Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. J Biol Chem 279: 19064-19073.
33. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, et al. (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973-985.
34. Komáromy AM, Varner SE, de Juan E, Acland GM, Aguirre GD, (2006) Application of a new subretinal injection device in the dog. Cell Transplant 15: 511-519.
35. Mowat FM, Petersen-Jones SM, Williamson H, Williams DL, Luthert PJ, et al. (2008) Topographical characterization of cone photoreceptors and the area centralis of the canine retina. Mol Vis 14: 2518-2527.
36. Beltran WA, Rohrer H, Aguirre GD, (2005) Immunolocalization of ciliary neurotrophic factor receptor alpha (CNTFRalpha) in mammalian photoreceptor cells. Mol Vis 11: 232-244.